Deciphera Pharmaceuticals’ Qinlock (ripretinib) Receives the US FDA’s Approval to Treat 4L Gastrointestinal Stromal Tumor

 Deciphera Pharmaceuticals’ Qinlock (ripretinib) Receives the US FDA’s Approval to Treat 4L Gastrointestinal Stromal Tumor

Shots:

  • The approval is based on P-III INVICTUS study including combined safety results from the P-I study which assessing of Qinlock (150mg, qd) vs PBO in ratio (2:1) in patients with advanced GIST whose previous therapies have included imatinib, sunitinib, and regorafenib to evaluate its safety, tolerability, and efficacy
  • The study demonstrated median PFS (6.3 mos. vs 1.0 mos.), reduced the risk of disease progression or death by 85%, mORR of 9.4%, mOS (15.1 mos. vs 6.6 mos.), reduced the risk of death by 64%
  • Qinlock (ripretinib) is kinase inhibitor targeted to treat adult patients with advanced gastrointestinal stromal tumor (GIST)

Click here to read full press release/ article | Ref: Deciphera | Image: Deciphera

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post